An Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Stella

Recruiting

Back to Multiple Sclerosis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(13 sites)

United States

Research Site, Tucson, Arizona

Research Site, Aurora, Colorado

Research Site, Washington D.C., District of Columbia

Research Site, St Louis, Missouri

Research Site, New York, New York

Key details

Phase

Early testing

Sponsor

AstraZeneca

Enrollment target

~24 participants

Started

December 2025

Primary completion

December 2028

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov